{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021538","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.443407+00:00","generated_at":"2026-05-16T22:20:10.886876+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xtant Medical Q3 revenue $33.3M (+19% YoY); net income $1.3M vs loss","bullets":["Revenue $33.3M (19% YoY); gross margin 66.1% vs 58.4%; net income $1.3M ($0.01 EPS) vs loss $5.0M (-$0.04 EPS).","Adjusted EBITDA $4.5M vs loss $1.0M in prior year quarter; cash from operations $4.6M (vs $1.7M used).","FY25 revenue guidance reiterated $131-135M (+11-15% YoY).","Pending sale of non-core Coflex/CoFix assets and OUS businesses to Companion Spine expected to close by year-end 2025.","Launched CollagenX bovine collagen particulate for surgical wound closure; potential across entire biologics portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021538","json":"https://secwatch.observer/filing/0001493152-25-021538.json","markdown":"https://secwatch.observer/filing/0001493152-25-021538.md","text":"https://secwatch.observer/filing/0001493152-25-021538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315225021538/0001493152-25-021538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315225021538/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:20:10.886876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}